Susan H Fox

Susan H Fox

UNVERIFIED PROFILE

Are you Susan H Fox?   Register this Author

Register author
Susan H Fox

Susan H Fox

Publications by authors named "Susan H Fox"

Are you Susan H Fox?   Register this Author

100Publications

1651Reads

48Profile Views

Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.

Clin Geriatr Med 2020 Feb 6;36(1):105-118. Epub 2019 Sep 6.

The Edmond J. Safra Program in Parkinson Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Krembil Research Institute, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cger.2019.09.004DOI Listing
February 2020

Diagnostic delay in Parkinson's disease caused by PRKN mutations.

Parkinsonism Relat Disord 2019 06 10;63:217-220. Epub 2019 Jan 10.

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada; Division of Neurology, University of Toronto, Toronto, Ontario, Canada; Krembil Brain Institute, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.01.010DOI Listing
June 2019

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Neuropharmacology 2019 03 1;147:11-27. Epub 2018 Jun 1.

Krembil Research Institute, University Health Network, Toronto, ON, Canada; Atuka Inc., Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2018.05.035DOI Listing
March 2019

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Eur J Neurosci 2019 Feb 15;49(3):399-409. Epub 2018 Nov 15.

Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejn.14173DOI Listing
February 2019

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Ann Neurol 2018 12 30;84(6):797-811. Epub 2018 Nov 30.

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ana.25364
Publisher Site
http://dx.doi.org/10.1002/ana.25364DOI Listing
December 2018

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

J Pharmacol Exp Ther 2018 11 7;367(2):373-381. Epub 2018 Aug 7.

Adamas Pharmaceuticals, Inc., Emeryville, California (E.F.B., C.B., J.D.S.H., J.T.N.); Atuka Inc, Toronto, Ontario, Canada (T.H.J., M.P.H., P.A.H., J.M.B.); Krembil Research Institute, University Health Network, Toronto, Ontario, Canada (T.H.J., S.H.F., J.M.B.); and Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada (S.H.F.)

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.118.24
Publisher Site
http://dx.doi.org/10.1124/jpet.118.247650DOI Listing
November 2018

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.

J Neuroeng Rehabil 2018 11 6;15(1):97. Epub 2018 Nov 6.

Toronto Rehabilitation Institute, University Health Network, 550 University Ave, Toronto, ON, M5G 2A2, Canada.

View Article

Download full-text PDF

Source
https://jneuroengrehab.biomedcentral.com/articles/10.1186/s1
Publisher Site
http://dx.doi.org/10.1186/s12984-018-0446-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219082PMC
November 2018

Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.

Mov Disord 2018 10;33(10):1560

Edmond J Safra Program in Parkinson Disease, Movement Disorder Clinic, Toronto Western Hospital, Division of Neurology, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27496DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214624PMC
October 2018

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.

Mov Disord 2018 08 23;33(8):1248-1266. Epub 2018 Mar 23.

Cure Huntington's Disease Initiative (CHDI) Management/CHDI Foundation, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27372DOI Listing
August 2018

Update in therapeutic strategies for Parkinson's disease.

Curr Opin Neurol 2018 08;31(4):439-447

Edmond J. Safra Program in Parkinson's Disease and The Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000579DOI Listing
August 2018

Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.

Parkinsonism Relat Disord 2018 08 5;53:42-45. Epub 2018 May 5.

Toronto Rehabilitation Institute, University Health Network, 550 University Ave, Toronto, Ontario, M5G 2A2, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College St, Room 407, Toronto, Ontario, M5S 3G9, Canada; Department of Computer Science, University of Toronto, 10 King's College Road, Room 3302, Toronto, Ontario, M5S 3G4, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.04.036DOI Listing
August 2018

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Neuropharmacology 2018 03 29;131:116-127. Epub 2017 Nov 29.

Atuka Inc.,Toronto, ON, Canada; Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2017.11.046DOI Listing
March 2018

Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.

Can J Neurol Sci 2018 01;45(1):23-29

1Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J.Safra Program in Parkinson's Disease,Toronto Western Hospital,University Health Network,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2017.245DOI Listing
January 2018

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

CMAJ 2018 01;190(2):E50-E52

Division of Neurology, Department of Medicine (Udow, Freitas, Fox, Lang), University of Toronto, Toronto, Ont.; Morton and Gloria Shulman Movement Disorders Clinic, and the Edmond J. Safra Program in Parkinson's Disease (Udow, Freitas, Fox, Lang), Toronto Western Hospital, University Health Network, Toronto, Ont.; Section of Neurology, Department of Internal Medicine (Udow), University of Manitoba, Winnipeg, Man.; Deer Lodge Movement Disorders Centre (Udow), Winnipeg, Man.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1503/cmaj.170361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770252PMC
January 2018

Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease.

Mov Disord Clin Pract 2018 Jan-Feb;5(1):66-74. Epub 2017 Nov 27.

Division of Neurology Department of Medicine University of Toronto Toronto Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174478PMC
November 2017

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Mov Disord 2017 06 30;32(6):893-903. Epub 2017 Mar 30.

Avanir Pharmaceuticals, Inc, Aliso Viejo, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26976DOI Listing
June 2017

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

ACS Chem Neurosci 2017 05 5;8(5):973-986. Epub 2017 May 5.

Janssen Vaccines & Prevention B.V. , Archimedesweg 4, 2333 CN Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.6b00440DOI Listing
May 2017

Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Semin Neurol 2017 04 16;37(2):147-157. Epub 2017 May 16.

Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0037-1602423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990008PMC
April 2017

Integrating Patient Concerns into Parkinson's Disease Management.

Curr Neurol Neurosci Rep 2017 01;17(1)

Division of Neurology, University of Malaya, Kuala Lumpur, Malaysia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-017-0717-2DOI Listing
January 2017

The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations.

Mov Disord Clin Pract 2017 Sep-Oct;4(5):698-709. Epub 2017 Jan 23.

Movement Disorder Unit and E. J. Safra Parkinson Disease Program Toronto Western Hospital University Health Network University of Toronto Toronto Ontario Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174444PMC
January 2017

Novel Levodopa Formulations for Parkinson's Disease.

CNS Drugs 2016 11;30(11):1079-1095

Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-016-0386-8DOI Listing
November 2016

Erratum to: Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Drugs 2016 09;76(13):1319

Morton and Gloria Shulman Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, 7th Floor, McLaughlin Pavilion, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0624-xDOI Listing
September 2016

Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism.

Can J Neurol Sci 2016 Sep 12;43(5):697-702. Epub 2016 Aug 12.

2University of Alberta,Edmonton,Alberta,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2016.279DOI Listing
September 2016

Treating the Motor Symptoms of Parkinson Disease.

Continuum (Minneap Minn) 2016 Aug;22(4 Movement Disorders):1064-85

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000355DOI Listing
August 2016

Patient Management Problem.

Authors:
Susan H Fox

Continuum (Minneap Minn) 2016 Aug;22(4 Movement Disorders):1321-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000361DOI Listing
August 2016

Patient Management Problem-Preferred Responses.

Authors:
Susan H Fox

Continuum (Minneap Minn) 2016 Aug;22(4 Movement Disorders):1327-36

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.CON.0000491170.82888.0bDOI Listing
August 2016

Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia.

Can J Neurol Sci 2016 Jul 3;43(4):462-71. Epub 2016 May 3.

1Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease,Toronto Western Hospital,University Health Network,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2016.35DOI Listing
July 2016

Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Drugs 2016 07;76(11):1093-118

Morton and Gloria Shulman Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, 7th Floor, McLaughlin Pavilion, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0600-5DOI Listing
July 2016

Nondopaminergic treatments for Parkinson's disease: current and future prospects.

Neurodegener Dis Manag 2016 06 27;6(3):249-68. Epub 2016 May 27.

Movement Disorders Clinic, Division of Neurology, University of Toronto, Toronto Western Hospital, 399 Bathurst Street MCL7-412, Toronto, ON M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2016-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976881PMC
June 2016

The long-term outcome of orthostatic tremor.

J Neurol Neurosurg Psychiatry 2016 Feb 13;87(2):167-72. Epub 2015 Mar 13.

Department of Neurology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France CRICM UPMC/INSERM UMR 1127 CNRS UMR7225 Brain and Spine Institute, Paris, France Pierre Marie Curie Paris-6 University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2014-309942DOI Listing
February 2016

Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action.

Mov Disord Clin Pract 2016 Mar-Apr;3(2):116-124. Epub 2015 Dec 30.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease Toronto Western Hospital University of Toronto Toronto Ontario Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178758PMC
December 2015

What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?

Parkinsonism Relat Disord 2015 Nov 25;21(11):1349-54. Epub 2015 Sep 25.

Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2015.09.044DOI Listing
November 2015

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Neuropharmacology 2015 Oct 10;97:306-11. Epub 2015 Jun 10.

Toronto Western Research Institute, University Health Network, 60 Leonard Ave., Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2015.05.033DOI Listing
October 2015

Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia.

Mov Disord Clin Pract 2016 Mar-Apr;3(2):184-187. Epub 2015 Oct 27.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease Toronto Western Hospital University of Toronto Toronto Ontario Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353362PMC
October 2015

Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.

Curr Top Behav Neurosci 2015 ;22:221-35

Toronto Western Research Institute, University of Toronto, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/7854_2014_352DOI Listing
September 2015

Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD.

Mov Disord 2015 May 8;30(6):786. Epub 2015 Apr 8.

Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26222DOI Listing
May 2015

Orthostatic hypotension in Parkinsonism: What is it and how can we treat it?

Mov Disord 2015 Apr 11;30(5):601-3. Epub 2015 Mar 11.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26179DOI Listing
April 2015

Tremor-Predominant Fragile X-Associated Tremor/Ataxia Syndrome in a Female.

Mov Disord Clin Pract 2015 Mar 30;2(1):45-46. Epub 2014 Dec 30.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease Toronto Western Hospital University Health Network Toronto Ontario Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353491PMC
March 2015

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Synapse 2015 Mar;69(3):99-102

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.21801DOI Listing
March 2015

Helicobacter pylori infection is associated with worse severity of Parkinson's disease.

Parkinsonism Relat Disord 2015 Mar 18;21(3):221-5. Epub 2014 Dec 18.

Division of Neurology and the Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, University of Malaya, Kuala Lumpur, Malaysia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.12.009DOI Listing
March 2015

Monoamine reuptake inhibitors in Parkinson's disease.

Parkinsons Dis 2015 25;2015:609428. Epub 2015 Feb 25.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/609428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355567PMC
March 2015

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Behav Pharmacol 2015 Feb;26(1-2):101-8

aToronto Western Research Institute bDivision of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/behaviouralpharm/2015/02000/L_7
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FBP.0000000000000096DOI Listing
February 2015

Clinical spectrum of levodopa-induced complications.

Mov Disord 2015 Jan 8;30(1):80-9. Epub 2014 Dec 8.

Movement Disorder Centre, Edmond J Safra Program in Parkinson Research, Toronto Western Hospital, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26125DOI Listing
January 2015

New treatments for the motor symptoms of Parkinson's disease.

Expert Rev Clin Pharmacol 2014 Nov;7(6):761-77

Division of Neurology, Onze-Lieve-Vrouw Hospital, Moorselbaan 164, 9300 Aalst, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2014.966812DOI Listing
November 2014

'Don't delay, start today': delaying levodopa does not delay motor complications.

Brain 2014 Oct;137(Pt 10):2628-30

Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awu212DOI Listing
October 2014

Famotidine, a Histamine H Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study.

Mov Disord Clin Pract 2014 Sep 26;1(3):219-224. Epub 2014 Jun 26.

Division of Neurology Movement Disorders Center and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, University of Toronto Toronto Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182979PMC
September 2014

Emerging drugs for levodopa-induced dyskinesia.

Expert Opin Emerg Drugs 2014 Sep 22;19(3):415-29. Epub 2014 Aug 22.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2014.955014DOI Listing
September 2014

Small intestinal bacterial overgrowth in Parkinson's disease.

Parkinsonism Relat Disord 2014 May 2;20(5):535-40. Epub 2014 Mar 2.

Faculty of Medicine (Divisions of Neurology and Gastroenterology), University of Malaya, Kuala Lumpur, Malaysia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.02.019DOI Listing
May 2014

Understanding conversion disorders: back to Freud's theory.

Mov Disord 2014 May;29(6):720

Movement Disorder Center, Edmond J. Safra Program in Parkinson Research, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25907DOI Listing
May 2014

Pimavanserin as treatment for Parkinson's disease psychosis.

Authors:
Susan H Fox

Lancet 2014 Feb 1;383(9916):494-6. Epub 2013 Nov 1.

Movement Disorder Clinic, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada M5T 2S8. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)62157-1DOI Listing
February 2014

Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Neurotherapeutics 2014 Jan;11(1):78-91

Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-013-0238-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899484PMC
January 2014

New methods of preventing neurodegeneration? Lessons from prion diseases.

Mov Disord 2014 Jan 17;29(1):35. Epub 2013 Dec 17.

Morton & Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25782DOI Listing
January 2014

Subthalamic nucleus and striatum: the red and green signals to regulate the traffic of basal ganglia circuitry.

Mov Disord 2013 Nov 21;28(13):1802. Epub 2013 Oct 21.

Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25694DOI Listing
November 2013

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Neuropharmacology 2013 Oct 14;73:337-47. Epub 2013 Jun 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2013.06.005DOI Listing
October 2013

The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Exp Brain Res 2013 Oct 28;230(4):463-76. Epub 2013 Jun 28.

Department of Pharmacology, Faculty of Medicine, University of Montréal, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00221-013-3621-2DOI Listing
October 2013

Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:
Susan H Fox

Drugs 2013 Sep;73(13):1405-15

Movement Disorders Clinic, Division of Neurology, University of Toronto, Toronto Western Hospital, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0105-4DOI Listing
September 2013

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

Prog Neuropsychopharmacol Biol Psychiatry 2013 Jun 7;43:151-6. Epub 2013 Jan 7.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02785846120031
Publisher Site
http://dx.doi.org/10.1016/j.pnpbp.2012.12.008DOI Listing
June 2013

Metabolic disorders causing movement disorders in childhood; an addition to the list.

Authors:
Susan H Fox

Mov Disord 2013 May;28(5):584

Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25434DOI Listing
May 2013

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.

Expert Opin Investig Drugs 2013 Apr 15;22(4):411-21. Epub 2013 Feb 15.

University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2013.769957DOI Listing
April 2013

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Parkinsonism Relat Disord 2013 Feb 14;19(2):260-4. Epub 2012 Aug 14.

Division of Brain, Imaging & Behaviour, Systems Neuroscience, Toronto Western Research Institute, 399 Bathurst Street, MP-12-303, Toronto, ON M5T2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.07.001DOI Listing
February 2013

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.

Mov Disord 2013 Feb 5;28(2):131-44. Epub 2012 Dec 5.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25273DOI Listing
February 2013

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Pharmacol Rev 2013 Jan 10;65(1):171-222. Epub 2013 Jan 10.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.111.005678DOI Listing
January 2013

Drug treatments for the neuropsychiatric complications of Parkinson's disease.

Expert Rev Neurother 2012 Dec;12(12):1439-49

University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ern.12.142DOI Listing
December 2012

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Neuropharmacology 2012 Oct 18;63(5):829-36. Epub 2012 Jun 18.

Toronto Western Research Institute, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2012.06.012DOI Listing
October 2012

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

Mov Disord 2012 Sep 13;27(11):1373-8. Epub 2012 Sep 13.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25133DOI Listing
September 2012

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

J Pharmacol Exp Ther 2012 Aug 22;342(2):576-85. Epub 2012 May 22.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.112.195693DOI Listing
August 2012

Improved viability of stem cell transplants in animal models of Parkinson's disease.

Authors:
Susan H Fox

Mov Disord 2012 Jun;27(7):814

Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25036DOI Listing
June 2012

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Mov Disord 2012 May 14;27(6):735-42. Epub 2012 Mar 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24964DOI Listing
May 2012

Improvement of apathy after levofloxacin treatment: an N-of-1 study.

Neurologist 2012 May;18(3):146-8

Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NRL.0b013e318251eb23DOI Listing
May 2012

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Neurobiol Aging 2012 Jan 18;33(1):194.e5-15. Epub 2010 Jun 18.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.035DOI Listing
January 2012

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Neurobiol Aging 2012 Jan 3;33(1):207.e9-19. Epub 2010 Nov 3.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.09.011DOI Listing
January 2012

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

J Pharmacol Exp Ther 2011 Oct 22;339(1):2-8. Epub 2011 Jul 22.

Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.111.184093DOI Listing
October 2011

The serotonergic system in Parkinson's disease.

Prog Neurobiol 2011 Oct 22;95(2):163-212. Epub 2011 Aug 22.

Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pneurobio.2011.08.004DOI Listing
October 2011

Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation.

J Neurol Neurosurg Psychiatry 2011 Apr 28;82(4):364-8. Epub 2010 Jul 28.

Movement Disorders Centre, Division of Neurology, Toronto Western Hospital, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp.2009.176198DOI Listing
April 2011

Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype.

Mov Disord 2011 Mar 21;26(4):753-5. Epub 2011 Jan 21.

Movement Disorder Clinic, Toronto Western Hospital, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23510DOI Listing
March 2011

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.

Prog Brain Res 2010 ;184:133-57

Division of Neurology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0079-6123(10)84007-5DOI Listing
January 2011

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Mov Disord 2010 Oct;25(13):2084-93

Division of Brain, Imaging, and Behaviour-Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23172DOI Listing
October 2010

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Mov Disord 2010 Jul;25(10):1379-90

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23069DOI Listing
July 2010

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Mov Disord 2010 Jul;25(10):1399-408

Division of Brain Imaging & Behaviour Systems - Neuroscience, Toronto Western Research Institute,Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23083DOI Listing
July 2010

Serotonin 2A receptors and visual hallucinations in Parkinson disease.

Arch Neurol 2010 Apr;67(4):416-21

Vivian M. Rakoff PET Centre, Toronto Western Hospital, Toronto, Ontario, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneurol.2010.35DOI Listing
April 2010